Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Director · Chief Executive Officer · 10% owner | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,229 |
Ending reported balance
After 2026-08-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-05 · Exercise / conversion · Acquired 45,004 · Balance 52,233 F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Row 2 · 2026-08-05 · Sale · Disposed 45,004 · Balance 7,229 F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $209.28 and $216.35. Row 3 · 2026-08-06 · Exercise / conversion · Acquired 4,660 · Balance 11,889 F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Row 4 · 2026-08-06 · Sale · Disposed 4,660 · Balance 7,229 F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $212.41 and $216.36. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $212.01 · Expires 2027-03-15 | Direct | 4,660 |
Reported balance
After 2026-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-05 · Exercise / conversion · Disposed 45,004 · Balance 4,660 F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $213.95 · Expires 2027-03-15 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-06 · Exercise / conversion · Disposed 4,660 · Balance 0 F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,344,500 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 7,344,500 F6: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $209.28 and $216.35.
F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $212.41 and $216.36.
F6: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,220 | $0.00 Strike: $120.17 | $0.00 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · derivative · entry 8 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 441,900 Underlying: Common Stock · 19,220 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| October 06, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 19,220 | $120.17 | $2,309,667.40 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $119.62 and $120.67. Read SEC document |
| October 06, 2025 Filed Oct 9, 2025 01:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 19,220 | $8.02 | $154,144.40 |
DisclosureSEC source: 0001193125-25-234881 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 16, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,719 | $0.00 Strike: $114.19 | $0.00 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · derivative · entry 10 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,120 Underlying: Common Stock · 19,719 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options within the next year. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 16, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 19,719 | $114.19 | $2,251,712.61 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · nonDerivative · entry 6 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F6 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $113.01 and $116.10. Read SEC document |
| September 16, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 19,719 | $8.02 | $158,146.38 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · nonDerivative · entry 5 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options within the next year. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,254 | $0.00 Strike: $117.37 | $0.00 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · derivative · entry 9 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 480,839 Underlying: Common Stock · 15,254 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options within the next year. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 15,254 | $117.37 | $1,790,361.98 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · nonDerivative · entry 4 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $116.70 and $118.44. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 15,254 | $8.02 | $122,337.08 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · nonDerivative · entry 3 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options within the next year. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,907 | $0.00 Strike: $118.96 | $0.00 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · derivative · entry 8 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 496,093 Underlying: Common Stock · 27,907 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options within the next year. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 27,907 | $118.96 | $3,319,816.72 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · nonDerivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,229 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $117.81 and $122.54. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 23:36 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 27,907 | $8.02 | $223,814.14 |
DisclosureSEC source: 0001193125-25-205260 · ownership.xml · nonDerivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options within the next year. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 00:51 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantPerformance Stock Units · Derivative | 28,609 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-027063 · ownership.xml · derivative · entry 3 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,609 Underlying: Common Stock · 28,609 shares Expires not disclosed F4 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date. F5 · derivative.expiration_date: Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 00:51 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 28,609 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-027063 · ownership.xml · derivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,609 Underlying: Common Stock · 28,609 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 00:51 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 28,887 | $0.00 Strike: $137.75 | $0.00 |
DisclosureSEC source: 0000950170-25-027063 · ownership.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,887 Underlying: Common Stock · 28,887 shares Expires 2035-02-20 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 21, 2029. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 47,886 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023354 · ownership.xml · derivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,886 Underlying: Common Stock · 47,886 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 87,192 | $0.00 Strike: $84.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023354 · ownership.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,192 Underlying: Common Stock · 87,192 shares Expires 2034-02-26 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 27, 2028. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:16 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 62,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016459 · doc4.xml · derivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,400 Underlying: Common Stock · 62,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:16 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,032 | $0.00 Strike: $65.32 | $0.00 |
DisclosureSEC source: 0001209191-23-016459 · doc4.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,032 Underlying: Common Stock · 110,032 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 2, 2027. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:04 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 110,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017162 · doc4.xml · derivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,861 Underlying: Common Stock · 110,861 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:04 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 209,655 | $0.00 Strike: $29.91 | $0.00 |
DisclosureSEC source: 0001209191-22-017162 · doc4.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,655 Underlying: Common Stock · 209,655 shares Expires 2032-03-03 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 4, 2026. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:45 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 51,715 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010806 · doc4.xml · derivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,715 Underlying: Common Stock · 51,715 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 5, 2025. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 5, 2025. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:45 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 97,155 | $0.00 Strike: $65.02 | $0.00 |
DisclosureSEC source: 0000899243-21-010806 · doc4.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,155 Underlying: Common Stock · 97,155 shares Expires 2031-03-04 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 5, 2025. Read SEC document |
| March 17, 2020 Filed Mar 20, 2020 01:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 51,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-004012 · edgar.xml · derivative · entry 2 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,691 Underlying: Common Stock · 51,691 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 17, 2020 Filed Mar 20, 2020 01:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 168,776 | $0.00 Strike: $45.14 | $0.00 |
DisclosureSEC source: 0001179110-20-004012 · edgar.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,776 Underlying: Common Stock · 168,776 shares Expires 2030-03-16 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 17, 2024. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 20:45 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 68,837 | $0.00 Strike: $17.61 | $0.00 |
DisclosureSEC source: 0001179110-19-011013 · edgar.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,837 Underlying: Common Stock · 68,837 shares Expires 2029-10-09 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on October 10, 2023; provided, that the vesting of the option will be accelerated such that 100% of the option will become fully vested upon the achievement of certain clinical, operational, and/or other milestones (approved by the compensation committee) prior to, on, or about December 31, 2019. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:07 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 319,212 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001104659-19-016573 · a4.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,212 Underlying: Common Stock · 319,212 shares Expires 2029-03-18 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 19, 2023. Read SEC document |
| March 12, 2018 Filed Apr 5, 2018 14:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 187,628 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001104659-18-022600 · a4.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,628 Underlying: Common Stock · 187,628 shares Expires 2028-03-11 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 12, 2022. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 21:04 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 149,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001104659-17-017647 · a4.xml · derivative · entry 1 TABUTEAU HERRIOT · CIK 0001219927 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,000 Underlying: Common Stock · 149,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.